Cryo-Cell Income from Continuous Operations 2010-2024 | CCEL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cryo-Cell income from continuous operations from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change

Cryo-Cell Income from Continuous Operations 2010-2024 | CCEL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Related Stocks
Company Name	Market Cap
Elevance Health (ELV)	$95.8B
Cencora (COR)	$49B
DiDi Global (DIDIY)	$23.3B
ICON (ICLR)	$17.5B
Natera (NTRA)	$16.7B
Viatris (VTRS)	$15.4B
Avantor (AVTR)	$14.8B
Revvity (RVTY)	$14.6B
BioMerieux (BMXMF)	$12.9B
CochLear (CHEOY)	$12.7B
Solventum (SOLV)	$12.2B
Medpace Holdings (MEDP)	$11.2B
Charles River Laboratories (CRL)	$11B
Doximity (DOCS)	$10.8B
HealthEquity (HQY)	$8.7B
Sonic Healthcare (SKHHY)	$8.5B
Bausch + Lomb (BLCO)	$6.9B
Life Times (LTH)	$5B
Sotera Health (SHC)	$4.4B
Organon (OGN)	$4B
Surgery Partners (SGRY)	$3.8B
BrightSpring Health Services (BTSG)	$3.4B
PACS (PACS)	$3.1B
Concentras Parent (CON)	$2.6B
Alignment Healthcare (ALHC)	$2.5B
Ardent Health Partners (ARDT)	$2.4B
Premier (PINC)	$2.3B
GeneDx Holdings (WGS)	$2.1B
Ryman Healthcare (RYHTY)	$2B
GoodRx Holdings (GDRX)	$1.8B